000088222 001__ 88222
000088222 005__ 20200716101454.0
000088222 0247_ $$2doi$$a10.1016/j.ejso.2019.03.017
000088222 0248_ $$2sideral$$a111310
000088222 037__ $$aART-2019-111310
000088222 041__ $$aeng
000088222 100__ $$aBaena Fustegueras, J.A.
000088222 245__ $$aMagnetic detection of sentinel lymph node in papillary thyroid carcinoma: The MAGIC-PAT study results
000088222 260__ $$c2019
000088222 5060_ $$aAccess copy available to the general public$$fUnrestricted
000088222 5203_ $$aIntroduction: Despite the controversy concerning sentinel lymph node biopsy (SLNB) in papillary thyroid carcinoma (PTC), successful detection rates can be achieved by radioguidance and vital dyeing. However, the drawbacks in both techniques are notable. Magnetic-guided SLNB (mSLNB) using superparamagnetic iron oxide (SPIO) nanoparticles is appealing as an alternative procedure.
Materials and Methods: mSLNB using the Sentimag-Sienna System ® , total thyroidectomy and central compartment dissection (CCD) were performed on all PTC patients. Lymph node involvement was assessed by postoperative pathological examination.
Results: From 2014 to 2016, 33 consecutive patients with PTC were enrolled in the study. A total of 20 patients met the eligibility. mSLNB succeeded in 16 patients, with a detection rate of 80%. A median of two SLN per patient were detected. A median of 10.5 non-sentinel lymph nodes (NSLN) from CCD were examined. Among the patients, 56.25% (9/16) had no metastatic nodes, while 12.5% (2/16) had exclusively SLN involvement. No false negative cases were found. The agreement between SLN and NSLN status was 87.5%. The prediction of NSLN involvement by SLN status showed 100% sensitivity, 81.8% specificity, 71.4% PPV and 100% NPV. Subsequently, mSLNB and the final pathological analysis would discriminate 43.75% (7/16) of patients who would certainly benefit from CCD whilst 56.25% of the total would confirm an unnecessary lymphadenectomy and avoid morbidity.
Conclusion: mSLNB showed satisfactory performance in PTC with clinical-negative nodes. We have shown mSLNB to be a good predictor of central compartment status that can improve the staging and management of PTC patients.
000088222 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000088222 590__ $$a3.959$$b2019
000088222 591__ $$aSURGERY$$b28 / 210 = 0.133$$c2019$$dQ1$$eT1
000088222 591__ $$aONCOLOGY$$b90 / 244 = 0.369$$c2019$$dQ2$$eT2
000088222 592__ $$a1.389$$b2019
000088222 593__ $$aMedicine (miscellaneous)$$c2019$$dQ1
000088222 593__ $$aSurgery$$c2019$$dQ1
000088222 593__ $$aOncology$$c2019$$dQ1
000088222 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000088222 700__ $$aGonzález, F.H.
000088222 700__ $$aCalderó, S.G.
000088222 700__ $$ade la Fuente Juárez, M.C.
000088222 700__ $$aRos López, S.$$uUniversidad de Zaragoza
000088222 700__ $$aRiu, F.R.
000088222 700__ $$aPetit, N.M.
000088222 700__ $$aÁlvarez, P.M.
000088222 700__ $$aTorelló, A.L.
000088222 700__ $$aMatias-Guiu, X.
000088222 700__ $$aOlsina Kissler, J.J.
000088222 7102_ $$11004$$2090$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Cirugía
000088222 773__ $$g19, 30 (2019), 342-7$$pEur. j. surg. oncol.$$tEuropean Journal of Surgical Oncology$$x0748-7983
000088222 8564_ $$s169115$$uhttps://zaguan.unizar.es/record/88222/files/texto_completo.pdf$$yPostprint
000088222 8564_ $$s43228$$uhttps://zaguan.unizar.es/record/88222/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000088222 909CO $$ooai:zaguan.unizar.es:88222$$particulos$$pdriver
000088222 951__ $$a2020-07-16-09:08:48
000088222 980__ $$aARTICLE